Using tyrosine kinase inhibitors acting directly on the FGFR3 signaling, a similar effect on foramen magnum has been reported,(25) suggesting that, if well tolerated, a drug that acts directly on FGFR3 has the potential to impact the facies phenotype in achondroplasia. This evidence concerns the gene FGFR3 and achondroplasia.